Clinical trial
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild…
NCT00236574 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00236574 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment |
| Official title | A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease. |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dementia, Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Galantamine hydrobromide |
| Enrollment | 974 |
| Start date | May 1, 2001 |
| Completion | Nov 1, 2003 |
| First posted | Oct 12, 2005 |
| Last update posted | Jun 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: